Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Amylin analogue shows utility in obesity models
June 2017
SHARING OPTIONS:

COPENHAGEN, Denmark—Zealand Pharma A/S and Boehringer Ingelheim GmbH (BI) presented data at the Keystone Symposia “Neuronal Control of Appetite, Metabolism and Weight/Gastrointestinal Control of Metabolism” demonstrating that ZP4982, a novel long-acting amylin analogue, prevents the development of obesity in preclinical models. The two companies have developed amylin analogues using a peptide approach, and BI plans to advance one lead molecule into a Phase 1 trial in 2017, which would trigger a milestone payment to Zealand.
 
Adam Steensberg, senior vice president, chief medical and development officer of Zealand, said: “Zealand has two collaborations with Boehringer Ingelheim and is excited to report progress on the amlyin program. Our amylin analogue, which has differentiation potential due to its long-acting profile, has shown significant metabolic benefits in preclinical obesity and diabetes models. We look forward to the initiation of clinical development of a lead molecule in 2017 to further explore its potential.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.